FDA Relaxes Avandia Restrictions

Drug Industry Daily
A A
Three years after placing heavy restrictions on GlaxoSmithKline’s type 2 diabetes drug Avandia, the FDA said Monday it is relaxing those restrictions in line with its advisers’ recommendations.

To View This Article:

Login

Subscribe To Drug Industry Daily